WO1998040069A3 - Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine - Google Patents
Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine Download PDFInfo
- Publication number
- WO1998040069A3 WO1998040069A3 PCT/EP1998/001478 EP9801478W WO9840069A3 WO 1998040069 A3 WO1998040069 A3 WO 1998040069A3 EP 9801478 W EP9801478 W EP 9801478W WO 9840069 A3 WO9840069 A3 WO 9840069A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stabilization
- amino acid
- acid
- cyclodextrin
- cyclodextrin combinations
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT98919099T ATE209491T1 (de) | 1997-03-13 | 1998-03-13 | Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen |
BR9808581-6A BR9808581A (pt) | 1997-03-13 | 1998-03-13 | Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina |
US09/319,895 US6248758B1 (en) | 1997-03-13 | 1998-03-13 | Pharmaceutical antacid |
DE69802688T DE69802688T3 (de) | 1997-03-13 | 1998-03-13 | Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen |
SI9830069T SI0991407T2 (en) | 1997-03-13 | 1998-03-13 | Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations |
DK98919099T DK0991407T4 (da) | 1997-03-13 | 1998-03-13 | Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer |
CA002282513A CA2282513C (fr) | 1997-03-13 | 1998-03-13 | Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine |
AU72070/98A AU731186B2 (en) | 1997-03-13 | 1998-03-13 | Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations |
NZ337592A NZ337592A (en) | 1997-03-13 | 1998-03-13 | Stabilization of acid sensitive benzimidazoles with amino/cyclodextrin combinations |
JP53923798A JP4608031B2 (ja) | 1997-03-13 | 1998-03-13 | アミノ酸/シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化 |
PCT/EP1998/001478 WO1998040069A2 (fr) | 1997-03-13 | 1998-03-13 | Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine |
HU0002364A HU225587B1 (en) | 1997-03-13 | 1998-03-13 | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
SK1209-99A SK284811B6 (sk) | 1997-03-13 | 1998-03-13 | Farmaceutická formulácia a spôsob jej výroby |
KR1019997008327A KR100563764B1 (ko) | 1997-03-13 | 1998-03-13 | 아미노산과 시클로덱스트린과의 병용에 의한 산(酸) 민감성 벤즈이미다졸류의 안정화 방법 |
EP98919099.6A EP0991407B2 (fr) | 1997-03-13 | 1998-03-13 | Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine |
IL13165198A IL131651A0 (en) | 1997-03-13 | 1998-03-13 | A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same |
PL335571A PL191570B1 (pl) | 1997-03-13 | 1998-03-13 | Preparat farmaceutyczny i sposób wytwarzania preparatu farmaceutycznego |
NO19994409A NO327212B1 (no) | 1997-03-13 | 1999-09-10 | Farmasoytisk formulering omfattende benzimidazoler og aminosyre/cyklodekstrin-kombinasjoner samt fremgangsmate for fremstilling derav. |
HK00103624A HK1024182A1 (en) | 1997-03-13 | 2000-06-16 | Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97104200 | 1997-03-13 | ||
EP97104200.7 | 1997-03-13 | ||
PCT/EP1998/001478 WO1998040069A2 (fr) | 1997-03-13 | 1998-03-13 | Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine |
EP98919099.6A EP0991407B2 (fr) | 1997-03-13 | 1998-03-13 | Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998040069A2 WO1998040069A2 (fr) | 1998-09-17 |
WO1998040069A3 true WO1998040069A3 (fr) | 1998-12-17 |
Family
ID=8226585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001478 WO1998040069A2 (fr) | 1997-03-13 | 1998-03-13 | Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine |
Country Status (24)
Country | Link |
---|---|
US (1) | US6248758B1 (fr) |
JP (1) | JP4608031B2 (fr) |
KR (1) | KR100563764B1 (fr) |
CN (1) | CN1113649C (fr) |
AT (1) | ATE209491T1 (fr) |
AU (1) | AU731186B2 (fr) |
BR (1) | BR9808581A (fr) |
CA (1) | CA2282513C (fr) |
CZ (1) | CZ291842B6 (fr) |
DE (1) | DE69802688T3 (fr) |
DK (1) | DK0991407T4 (fr) |
ES (1) | ES2167891T5 (fr) |
HK (1) | HK1024182A1 (fr) |
HU (1) | HU225587B1 (fr) |
IL (1) | IL131651A0 (fr) |
NO (1) | NO327212B1 (fr) |
NZ (1) | NZ337592A (fr) |
PL (1) | PL191570B1 (fr) |
PT (1) | PT991407E (fr) |
SI (1) | SI0991407T2 (fr) |
SK (1) | SK284811B6 (fr) |
TR (1) | TR199902233T2 (fr) |
WO (1) | WO1998040069A2 (fr) |
ZA (1) | ZA982155B (fr) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
JP4127740B2 (ja) * | 1998-04-20 | 2008-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化したベンズイミダゾール系化合物含有組成物 |
US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
ES2149750T3 (es) * | 1999-01-06 | 2004-06-01 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos. |
IL130602A0 (en) * | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
DE19959419A1 (de) | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
CN1322850C (zh) * | 2000-06-02 | 2007-06-27 | 沈阳药科大学 | 盐酸尼卡地平粉针剂及其制备方法 |
US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
WO2002040034A1 (fr) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd. | Complexes de derives de phosphate |
GB2376231A (en) * | 2001-06-06 | 2002-12-11 | Cipla Ltd | Benzimidazole-cyclodextrin inclusion complex |
CN1547475B (zh) * | 2001-07-27 | 2010-12-15 | 生命健康科学有限公司 | 含电子转移试剂的磷酸酯衍生物的皮肤制剂 |
AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
GB2379854B (en) * | 2001-09-19 | 2006-04-19 | Walcom Animal Science | Dairy cow feed and the use thereof |
EP1460995B1 (fr) * | 2001-12-13 | 2010-11-10 | Vital Health Sciences Pty Ltd. | Transport transdermique de composes |
AU2003202557A1 (en) * | 2002-01-15 | 2003-07-30 | Nycomed Gmbh | Pantoprazole cyclodextrin inclusion complexes |
ITMI20021074A1 (it) * | 2002-05-20 | 2003-11-20 | Actimex S R L | Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
PT1524967E (pt) * | 2002-08-02 | 2008-04-03 | Ratiopharm Gmbh | Preparação farmacêutica contendo um composto de benzimidazole misturado com celulose microcristalina e método para a sua preparação. |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
ITMI20022549A1 (it) * | 2002-12-02 | 2004-06-03 | Actimex S R L | Composizione quaternaria comprendente come sostanza attiva la propolis. |
US20040109920A1 (en) * | 2002-12-04 | 2004-06-10 | Bioactives Llc | Coated carotenoid cyclodextrin complexes |
MXPA05007278A (es) * | 2003-01-17 | 2005-09-30 | Vital Health Sciences Pty Ltd | Compuestos que tienen propiedades anti-proliferativas. |
US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
AU2005202477B2 (en) * | 2004-03-03 | 2005-12-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
KR20050105565A (ko) * | 2004-04-30 | 2005-11-04 | 에스케이케미칼주식회사 | 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법 |
WO2005112637A1 (fr) * | 2004-05-14 | 2005-12-01 | Decode Chemistry, Inc. | Préparations à usage non parentéral comprenant des cyclodextrines hydrophobes |
US20060058276A1 (en) * | 2004-07-15 | 2006-03-16 | Oded Friedman | Processes for the preparation and purification of rocuronium bromide |
ATE494911T1 (de) * | 2004-08-03 | 2011-01-15 | Vital Health Sciences Pty Ltd | Träger für die enterale verabreichung |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005008412A1 (de) * | 2005-02-24 | 2006-09-07 | Ratiopharm Gmbh | Piperazinsalz des Omeprazols und dessen Enantiomere |
US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
ES2557475T3 (es) | 2005-06-17 | 2016-01-26 | Vital Health Sciences Pty Ltd. | Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
KR20080085839A (ko) * | 2005-12-23 | 2008-09-24 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | 사이토킨 조절 특성을 가진 화합물 |
EP1852108A1 (fr) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
PE20110235A1 (es) * | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
AU2007266574A1 (en) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
US7840305B2 (en) | 2006-06-28 | 2010-11-23 | 3M Innovative Properties Company | Abrasive articles, CMP monitoring system and method |
BRPI0815405A2 (pt) * | 2007-08-17 | 2015-02-03 | Boehringer Ingelheim Int | Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
AR072395A1 (es) * | 2008-06-30 | 2010-08-25 | Merck & Co Inc | Formulacion de dosificacion solida de telcagepant potasico |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
NZ604091A (en) * | 2008-08-15 | 2014-08-29 | Boehringer Ingelheim Int | Purin derivatives for use in the treatment of fab-related diseases |
KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
NZ592924A (en) | 2008-12-23 | 2014-05-30 | Boehringer Ingelheim Int | Salt forms of a xanthine derivative |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
WO2011120084A1 (fr) | 2010-03-30 | 2011-10-06 | Phosphagenics Limited | Timbre transdermique |
WO2011138421A1 (fr) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combinaison thérapeutique |
KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2012122586A1 (fr) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | Nouvelle composition |
EP3517539B1 (fr) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Dérivé de quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement du diabète de type i et ii |
CN102584633B (zh) * | 2011-12-16 | 2013-07-03 | 山东大学 | 一种赖氨酸α-氨基的苄氧羰基高效选择性保护方法及其产品 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体 |
WO2013174767A1 (fr) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
WO2016174664A1 (fr) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Compositions à désintégration par voie orale |
US20190105274A1 (en) * | 2015-07-13 | 2019-04-11 | Kyowa Hakko Bio Co., Ltd. | Tablets containing arginine at high concentration |
ES2981002T3 (es) | 2015-12-09 | 2024-10-04 | Avecho Biotechnology Ltd | Formulación farmacéutica |
CN106924179B (zh) * | 2015-12-29 | 2021-04-30 | 成都康弘药业集团股份有限公司 | 一种含有富马酸沃诺拉赞的液体制剂及其制备方法 |
EP4233840A3 (fr) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinaisons de linagliptine et de metformine |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
KR101829685B1 (ko) * | 2016-07-28 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성 및 용해도가 개선된 주사용 조성물 |
KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
ES2983921T3 (es) | 2016-12-21 | 2024-10-28 | Avecho Biotechnology Ltd | Proceso para fosforilar un alcohol complejo |
CN108324957B (zh) * | 2018-04-20 | 2021-04-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种s-羧甲基-l-半胱氨酸包合物及其肠溶制剂组合物 |
CN116585283A (zh) * | 2023-05-26 | 2023-08-15 | 桂林华信制药有限公司 | 兰索拉唑肠溶胶囊及其制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3427786A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Inklusionskomplexe von benzimidazolderivaten mit cyclodextrinen, deren herstellung und arzneimittel |
DE3427787A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel |
EP0444625A1 (fr) * | 1990-02-27 | 1991-09-04 | Hanmi Pharm. Ind. Co., Ltd. | Compositions d'omeprazole pour l'administration rectale |
KR920008161B1 (ko) * | 1990-02-19 | 1992-09-24 | 한미약품공업주식회사 | 오메프라졸 경구용 약제의 제조방법 |
WO1993013138A1 (fr) * | 1991-12-31 | 1993-07-08 | Sunkyong Industries Co., Ltd. | Medicaments enterosolubles administrables par voie orale contenant des composes instables en milieu acide |
JPH05194225A (ja) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
WO1994002140A1 (fr) * | 1992-07-17 | 1994-02-03 | Astra Aktiebolag | Composition pharmaceutique contenant un agent antiulcereux |
WO1996024338A1 (fr) * | 1995-02-09 | 1996-08-15 | Astra Aktiebolag | Nouvelle formulation pharmaceutique et procede afferent |
WO1996038175A1 (fr) * | 1995-06-02 | 1996-12-05 | Takeda Chemical Industries, Ltd. | Composition stabilisee comprenant un benzimidazole anti-ulcereux |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
UA41946C2 (uk) * | 1994-07-08 | 2001-10-15 | Астра Актієболаг | Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань |
JPH0948730A (ja) * | 1995-06-02 | 1997-02-18 | Takeda Chem Ind Ltd | 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物 |
-
1998
- 1998-03-13 TR TR1999/02233T patent/TR199902233T2/xx unknown
- 1998-03-13 PT PT98919099T patent/PT991407E/pt unknown
- 1998-03-13 DE DE69802688T patent/DE69802688T3/de not_active Expired - Lifetime
- 1998-03-13 CZ CZ19993128A patent/CZ291842B6/cs not_active IP Right Cessation
- 1998-03-13 WO PCT/EP1998/001478 patent/WO1998040069A2/fr not_active Application Discontinuation
- 1998-03-13 IL IL13165198A patent/IL131651A0/xx not_active IP Right Cessation
- 1998-03-13 AU AU72070/98A patent/AU731186B2/en not_active Ceased
- 1998-03-13 SI SI9830069T patent/SI0991407T2/xx unknown
- 1998-03-13 JP JP53923798A patent/JP4608031B2/ja not_active Expired - Fee Related
- 1998-03-13 SK SK1209-99A patent/SK284811B6/sk not_active IP Right Cessation
- 1998-03-13 HU HU0002364A patent/HU225587B1/hu not_active IP Right Cessation
- 1998-03-13 DK DK98919099T patent/DK0991407T4/da active
- 1998-03-13 ZA ZA982155A patent/ZA982155B/xx unknown
- 1998-03-13 KR KR1019997008327A patent/KR100563764B1/ko not_active IP Right Cessation
- 1998-03-13 AT AT98919099T patent/ATE209491T1/de active
- 1998-03-13 PL PL335571A patent/PL191570B1/pl unknown
- 1998-03-13 CN CN98803296A patent/CN1113649C/zh not_active Expired - Fee Related
- 1998-03-13 BR BR9808581-6A patent/BR9808581A/pt not_active Application Discontinuation
- 1998-03-13 ES ES98919099T patent/ES2167891T5/es not_active Expired - Lifetime
- 1998-03-13 CA CA002282513A patent/CA2282513C/fr not_active Expired - Fee Related
- 1998-03-13 US US09/319,895 patent/US6248758B1/en not_active Expired - Lifetime
- 1998-03-13 NZ NZ337592A patent/NZ337592A/xx not_active IP Right Cessation
-
1999
- 1999-09-10 NO NO19994409A patent/NO327212B1/no not_active IP Right Cessation
-
2000
- 2000-06-16 HK HK00103624A patent/HK1024182A1/xx not_active IP Right Cessation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3427786A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Inklusionskomplexe von benzimidazolderivaten mit cyclodextrinen, deren herstellung und arzneimittel |
DE3427787A1 (de) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel |
KR920008161B1 (ko) * | 1990-02-19 | 1992-09-24 | 한미약품공업주식회사 | 오메프라졸 경구용 약제의 제조방법 |
EP0444625A1 (fr) * | 1990-02-27 | 1991-09-04 | Hanmi Pharm. Ind. Co., Ltd. | Compositions d'omeprazole pour l'administration rectale |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
JPH05194225A (ja) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
WO1993013138A1 (fr) * | 1991-12-31 | 1993-07-08 | Sunkyong Industries Co., Ltd. | Medicaments enterosolubles administrables par voie orale contenant des composes instables en milieu acide |
WO1994002140A1 (fr) * | 1992-07-17 | 1994-02-03 | Astra Aktiebolag | Composition pharmaceutique contenant un agent antiulcereux |
WO1996024338A1 (fr) * | 1995-02-09 | 1996-08-15 | Astra Aktiebolag | Nouvelle formulation pharmaceutique et procede afferent |
WO1996038175A1 (fr) * | 1995-06-02 | 1996-12-05 | Takeda Chemical Industries, Ltd. | Composition stabilisee comprenant un benzimidazole anti-ulcereux |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 119, no. 22, 29 November 1993, Columbus, Ohio, US; abstract no. 234039, XP002079803 * |
CHEMICAL ABSTRACTS, vol. 124, no. 16, 15 April 1996, Columbus, Ohio, US; abstract no. 211738, XP002079802 * |
DATABASE WPI Week 9332, Derwent World Patents Index; AN 93-255964 [32], XP002079804 * |
S.J. HWANG ET AL.: "A COMPARATIVE STUDY ON THE PHARMACEUTICAL PROPERTIES OF RECTAL SUPPOSITORY CONTAINING OMEPRAZOLE COMPLEXES", YAKCHE HAKHOECHI, vol. 25, no. 3, 1995, pages 227 - 237 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998040069A3 (fr) | Stabilisation de benzimidazoles sensibles aux acides avec des combinaisons amino-cyclodextrine | |
AU3076700A (en) | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient | |
EP1589947B8 (fr) | Formulation pharmaceutique ayant un agent actif insoluble | |
WO2000041681A3 (fr) | FORMULATIONS DE MEDICAMENTS CONTENANT UN OPIOIDE ET UN α-AGONISTE | |
HUP0004310A3 (en) | Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents | |
WO2000040203A3 (fr) | Agents d'administration polymeres et composes d'agents d'administration | |
AU7962200A (en) | Novel indole derivatives and drugs containing the same as the active ingredient | |
DK1169024T3 (da) | Prægelatineret stivelse i en formulering med kontrolleret frigivelse | |
WO2000045800A3 (fr) | Effets immunosuppresseurs des derives de pteridine | |
AU2001278772A1 (en) | Benzoic acid derivatives and drugs containing the same as the active ingredient | |
CA2352915A1 (fr) | Compositions pharmaceutiques renfermant de la mupirocine | |
NO20006646D0 (no) | Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel | |
AU5647199A (en) | Carboxylic acid derivatives and drugs containing the same as the active ingredient | |
AR012868A1 (es) | COMPOSICIoN FARMACÉUTICA QUE COMPRENDE UN PÉPTIDO AGONISTA DE LHRH, UN ANTAGONISTA DE LHRH O UN PÉPTIDO DE GRF Y NICOTINAMIDA. | |
AU1650401A (en) | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | |
AU3669700A (en) | 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient | |
AU5443499A (en) | Carboxylic acid derivatives and drugs containing the same as the active ingredient | |
AU1650501A (en) | 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient | |
AU2023801A (en) | Dihalopropenyloxybenzene derivatives and pesticides containing the same as the active ingredient | |
CA2385867A1 (fr) | Formulation a action retarde contenant des derives de l'acide alpha-lipoic | |
RS50074B (sr) | Farmaceutski preparat koji sadrži paracetamol i drotaverin | |
AU1556601A (en) | 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | |
AU2827500A (en) | Fluorinated chalcone derivatives or salts thereof and drugs containing the same as the active ingredient | |
ES2130069A1 (es) | Preparacion farmaceutica con liberacion retardada del producto activo. | |
AU2002309047A1 (en) | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 131651 Country of ref document: IL Ref document number: 98803296.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2282513 Country of ref document: CA Ref document number: 2282513 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 337592 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-3128 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 120999 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09319895 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 539237 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/008374 Country of ref document: MX Ref document number: 1998919099 Country of ref document: EP Ref document number: 72070/98 Country of ref document: AU Ref document number: 1019997008327 Country of ref document: KR Ref document number: 1999/02233 Country of ref document: TR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-3128 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1998919099 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997008327 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 72070/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998919099 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-3128 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997008327 Country of ref document: KR |